Comparison of FDG-PET and Technetium-99m MIBI SPECT to Detect Metastatic Cervical Lymph Nodes in Well-differentiated Thyroid Carcinoma with Elevated Serum HTG but Negative I-131 Whole Body Scan

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4235-4238

  Wu, Hurng Sheng ^a   Huang, Wen Sheng ^b   Liu, Yao Chi ^b   Yen, Ruoh Fang ^c   Shen, Yeh You ^d   Kao, Chia Hung ^e  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cervical lymph nodes; FDG PET; Tc 99m MIBI SPECT; Well differentiated thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THYROGLOBULIN; THYROTROPIN;

ADULT; AGED; ARTICLE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; HUMAN; ISOTOPE LABELING; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCANNER;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 0344009641     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mazzaferri EL: Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 14: 315-332, 1987.
2. McCohaney WH, Hay ID, Wolner LB et al: Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61: 978-996, 1986.
3. Roelants V, De Nayer P, Bouckaert A and Beckers C: The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24: 722-727, 1997.
4. Filesi M, Signore A, Ventroni G et al: Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 39: 1542-1546, 1998.
5. Galloway RJ and Smallridge RC: Imaging in thyroid cancer. Endocrinol Metab Clin North Am 25: 93-113, 1996.
6. Samaan NA, Schultz PN, Haynie TP and Ordonez NG: Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60: 376-380, 1985.
7. 131I whole body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 41: 631-635, 2000.
8. Rubello D, Mazzarotto R and Casara D: The role of techentium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 27: 431-440, 2000.
9. Alnafisi NS, Driedger AA, Coates G et al: FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 41: 1010-1015, 2000.
10. Schlüter B, Bohuslavizki KH, Beyer W et al: Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42: 71-76, 2001.
11. Harwood J, Clark OH and Dunphy JE: Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 136: 107-112, 1978.
12. Chiu ML, Kronauge JF and Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 31: 1646-1653, 1990.
13. Hoh CK, Schiepers C, Seltzer MA et al: PET in oncology: Will it replace the other modalities? Semin Nucl Med 27: 94-106, 1977.
14. Mueller SP, Piotrowski B, Guth-Tougelides B and Reiners C: Tc-99m MIBI and Tl-201 uptake in thyroid carcinoma [abstract]. J Nucl Med 29(supp): 854, 1988.
15. Feine U, Lietzenmayer R, Hanke J-P et al: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37: 1468-1472, 1996.
16. Rubello D, Mazzarotto R and Casara D: The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 27: 431-440, 2000.
17. Yeo JS, Chung JK, So Y et al: F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23: 94-103, 2001.
18. Seabold JE, Gurll N, Schurrer ME et al: Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med 40: 1434-1440, 1999.